ARTICLE | Company News
Amgen, Bioject deal
December 17, 2001 8:00 AM UTC
AMGN exclusively licensed a modified version of BJCT’s B2000 needle-free injection system for use with certain AMGN therapeutics. AMGN will pay BJCT an upfront fee of $1 million, plus milestones and o...